Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery

666 adults taking single or dual antiplatelet therapy (aspirin or clopidogrel) for at least two weeks, with at least one cardiac risk factor, scheduled for elective non-cardiac surgery under general, spinal or regional anaesthesia (pooled from 5 RCTs).

Continuation of single or dual antiplatelet therapy (aspirin or clopidogrel) perioperatively.

Discontinuation of antiplatelet therapy or substitution with placebo for at least five days before surgery.

All-cause mortality at longest follow-up (up to six months) and all-cause mortality up to 30 days.hard clinical